trending Market Intelligence /marketintelligence/en/news-insights/trending/zug_dmrndzsndzszuaikaq2 content esgSubNav
In This List

AstraZeneca's blood disorder drug wins US FDA approval

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


AstraZeneca's blood disorder drug wins US FDA approval

The U.S. Food and Drug Administration approved AstraZeneca PLC's Lokelma to treat hyperkalemia in adults.

Hyperkalemia is a disorder characterized by high levels of potassium in the blood.

The approval for Lokelma, a highly selective, oral potassium-removing agent, is backed by three late-stage clinical studies. Data from one trial showed that 92% of patients on the drug achieved normal potassium levels within 48 hours from the start of the study.

In March, the European Commission approved Lokelma for the treatment of the same disease in adults.